Sponsors (18)
Introduced January 31, 2025 by Chris Pappas · Last progress January 31, 2025
The bill aims to blunt the fentanyl crisis by enabling faster, broader control and tougher penalties for fentanyl analogs while also opening some research and rescheduling pathways — but it does so at the cost of expanded criminal scope, higher enforcement and incarceration risks, regulatory uncertainty, and potential chilling effects on legitimate research and medical access.
Communities and people at risk of overdose: class-wide control plus lower quantity thresholds make it easier to criminally control many fentanyl analogs, which may reduce availability of novel fentanyls and overdoses.
Law enforcement and prosecutors: clearer statutory authority and updated, specific weight thresholds simplify charging decisions and prosecutions for fentanyl and analogues.
Scientists, clinicians, and patients: faster, more transparent research and rescheduling pathways (expedited research registration, standardized scientific criteria, and potential rescheduling to less-restrictive schedules) speed medical research and may improve access to certain fentanyl-related therapies.
Researchers, small manufacturers, hospitals, and some ordinary buyers: broad class-wide scheduling and expanded Schedule I coverage risk sweeping in chemically related but legitimate compounds, chilling research, product development, and legal commerce through uncertainty and potential criminal exposure.
Defendants, communities, and taxpayers: lowering weight thresholds and expanding penalties will increase the number of cases subject to harsher mandatory penalties, likely raising incarceration rates and government correctional costs.
Researchers and regulated entities: accelerated interim rules and faster effective dates may impose compliance costs and create enforcement risk based on rules that could change after public comment, increasing legal uncertainty and potential burdens before final procedures are settled.
Based on analysis of 9 sections of legislative text.
Classifies broad groups of fentanyl-related substances as Schedule I, adjusts penalty weight thresholds, creates HHS rescheduling/removal process, streamlines Schedule I research registration, and allows sentence relief when substances are later rescheduled or delisted.
Creates a permanent, class-wide Schedule I listing for “fentanyl-related substances” (FRS) defined by specific chemical modifications, and removes those classed substances from certain mandatory minimum quantity rules. It raises and recalibrates the weight thresholds that trigger enhanced federal penalties for fentanyl and specified fentanyl analogues in domestic and import/export crimes while excluding FRS from those quantity-based mandatory minimums. Establishes a fast, binding HHS procedure to request removal or rescheduling of FRS to lower schedules when scientific review shows lower abuse potential, adds a streamlined DEA research-registration pathway for Schedule I research, permits courts to seek sentence reductions when a substance is later rescheduled or delisted, requires the Attorney General to issue implementing rules within one year, and tasks GAO with a 4-year implementation and impact study.